Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic

By

Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic 

  • Melior’s therapeutic candidate, tolimidone, is:  
    • Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications 
    • A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies 

See more here

Comments are closed.